Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6086) 6086
Book Review (312) 312
Publication (199) 199
Book Chapter (19) 19
Conference Proceeding (8) 8
Newsletter (3) 3
Book / eBook (2) 2
Dissertation (2) 2
Web Resource (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5619) 5619
vinblastine - pharmacology (3345) 3345
humans (3301) 3301
animals (2913) 2913
male (1672) 1672
female (1645) 1645
oncology (1645) 1645
vinblastine (1611) 1611
pharmacology & pharmacy (1116) 1116
mice (1073) 1073
vinblastine - analogs & derivatives (1035) 1035
vinblastine - administration & dosage (960) 960
colchicine - pharmacology (925) 925
middle aged (892) 892
rats (849) 849
adult (843) 843
antineoplastic combined chemotherapy protocols - therapeutic use (840) 840
aged (746) 746
chemotherapy (715) 715
antineoplastic agents - pharmacology (649) 649
cancer (617) 617
microtubules - drug effects (611) 611
p-glycoprotein (544) 544
antineoplastic agents, phytogenic - pharmacology (519) 519
dose-response relationship, drug (513) 513
biochemistry & molecular biology (498) 498
tumor cells, cultured (463) 463
cell line (460) 460
time factors (458) 458
vinblastine - therapeutic use (455) 455
vinorelbine (450) 450
antineoplastic combined chemotherapy protocols - adverse effects (415) 415
kinetics (412) 412
drug resistance (403) 403
cell line, tumor (401) 401
vinblastine - adverse effects (390) 390
vinblastine - metabolism (388) 388
expression (384) 384
vincristine - pharmacology (373) 373
treatment outcome (371) 371
cell biology (363) 363
cisplatin - administration & dosage (360) 360
cells, cultured (359) 359
tubulin - metabolism (356) 356
cisplatin (353) 353
in vitro techniques (328) 328
lung neoplasms - drug therapy (327) 327
doxorubicin (319) 319
doxorubicin - pharmacology (318) 318
microtubules (316) 316
cells (309) 309
paclitaxel - pharmacology (308) 308
microscopy, electron (302) 302
drug resistance, neoplasm (297) 297
microtubules - metabolism (292) 292
multidrug resistance (292) 292
vincristine (292) 292
cell division - drug effects (289) 289
breast neoplasms - drug therapy (280) 280
paclitaxel (279) 279
mitosis - drug effects (277) 277
vinblastine - pharmacokinetics (277) 277
apoptosis (272) 272
cell survival - drug effects (270) 270
doxorubicin - administration & dosage (269) 269
tubulin (268) 268
verapamil - pharmacology (266) 266
atp-binding cassette, sub-family b, member 1 - metabolism (257) 257
research (255) 255
cytochalasin b - pharmacology (250) 250
carcinoma, non-small-cell lung - drug therapy (245) 245
drug resistance, multiple (244) 244
multidrug-resistance (243) 243
adolescent (231) 231
abridged index medicus (228) 228
antineoplastic agents - therapeutic use (221) 221
drug synergism (220) 220
proteins (219) 219
therapy (218) 218
apoptosis - drug effects (217) 217
colchicine (217) 217
tritium (212) 212
drugs (208) 208
in-vitro (208) 208
drug administration schedule (207) 207
deoxycytidine - analogs & derivatives (205) 205
survival analysis (201) 201
antineoplastic combined chemotherapy protocols - administration & dosage (200) 200
aged, 80 and over (198) 198
carcinoma (191) 191
neoplasm staging (191) 191
pharmacology/toxicology (190) 190
bleomycin - administration & dosage (185) 185
hodgkin disease - drug therapy (185) 185
binding sites (184) 184
cricetinae (180) 180
medicine & public health (178) 178
antineoplastic agents (176) 176
pharmacokinetics (176) 176
microtubules - physiology (175) 175
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5827) 5827
French (61) 61
Russian (56) 56
Japanese (48) 48
German (43) 43
Italian (24) 24
Chinese (22) 22
Spanish (6) 6
Polish (4) 4
Hungarian (3) 3
Romanian (2) 2
Bulgarian (1) 1
Danish (1) 1
Dutch (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Combinations of alkaloids affecting different molecular targets with the saponin digitonin can synergistically enhance trypanocidal activity against Trypanosoma brucei brucei
by Krstin, Sonja and Peixoto, Herbenya Silva and Wink, Michael
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 11/2015, Volume 59, Issue 11, pp. 7011 - 7017
The flagellate Trypanosoma brucei causes sleeping sickness in humans and nagana in animals. Only a few drugs are registered to treat trypanosomiasis, but those... 
SECONDARY METABOLITES | CANCER-CELLS | IN-VITRO | BLOOD-STREAM FORMS | RHODESIENSE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | PROLIFERATION | DRUG-RESISTANCE | CYTOTOXICITY | CHEMOTHERAPY | P-GLYCOPROTEIN | Models, Theoretical | Alkaloids - pharmacology | Emetine - pharmacology | Trypanosoma brucei brucei - drug effects | Benzophenanthridines - pharmacology | Drug Synergism | Berberine - pharmacology | Animals | Piperidines - pharmacology | Trypanocidal Agents - pharmacology | Harringtonines - pharmacology | Polyunsaturated Alkamides - pharmacology | Vinblastine - pharmacology | Benzodioxoles - pharmacology | Digitonin - pharmacology | Drug Combinations | Index Medicus | Experimental Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers
by Iduna Fichtner and Jana Rolff and Richie Soong and Jens Hoffmann and Stefanie Hammer and Anette Sommer and Michael Becker and Johannes Merk
Clinical Cancer Research, ISSN 1078-0432, 10/2008, Volume 14, Issue 20, pp. 6456 - 6468
Purpose: It was the aim of our study to establish an extensive panel of non-small cell lung cancer (NSCLC) xenograft models useful for the testing of novel... 
xenograft | NSCLC | erlotinib | mutational analysis | anti-EGFR therapy | cetuximab | biomarker | TARGETED THERAPY | KRAS MUTATIONS | GROWTH-FACTOR RECEPTOR | NUDE-MICE | TUMOR XENOGRAFTS | GEFITINIB | ONCOLOGY | GENE-EXPRESSION | TYROSINE KINASE INHIBITOR | EGFR MUTATIONS | ANTITUMOR-ACTIVITY | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Oligonucleotide Array Sequence Analysis | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Middle Aged | Drug Resistance, Neoplasm | Immunoblotting | Male | Gene Expression Profiling | Adenocarcinoma - metabolism | Biomarkers, Tumor - metabolism | Cetuximab | Disease Models, Animal | Genes, ras - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Etoposide - pharmacology | Mutation - genetics | Adenocarcinoma - drug therapy | Small Cell Lung Carcinoma - pathology | Carcinoma, Squamous Cell - drug therapy | Mice, Nude | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives | Erlotinib Hydrochloride | Paclitaxel - pharmacology | Prognosis | Carcinoma, Squamous Cell - metabolism | Deoxycytidine - pharmacology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Tumor Suppressor Protein p53 - genetics | Small Cell Lung Carcinoma - metabolism | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Vinblastine - analogs & derivatives | Polymerase Chain Reaction | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Radiation-Sensitizing Agents - pharmacology | Tumor Suppressor Protein p53 - metabolism | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Protein Kinase Inhibitors - pharmacology | Vinblastine - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents, Phytogenic - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Rational combinations of Trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
by Pegram, Mark D and Konecny, Gottfried E and O'Callaghan, Carminda and Beryt, Malgorzata and Pietras, Richard and Slamon, Dennis J
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2004, Volume 96, Issue 10, pp. 739 - 749
Background. Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers... 
TUMOR-CELL LINES | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | IN-VITRO | PACLITAXEL TAXOL(R) | ONCOLOGY | 1ST-LINE CHEMOTHERAPY | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | CLINICAL PHARMACOKINETICS | DOCETAXEL TAXOTERE(R) | Up-Regulation | Cyclophosphamide - analogs & derivatives | Paclitaxel - pharmacology | Taxoids - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Receptor, ErbB-2 - metabolism | Deoxycytidine - pharmacology | Transplantation, Heterologous | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Female | Gene Expression Regulation, Neoplastic - drug effects | Receptor, ErbB-2 - drug effects | Disease Models, Animal | Floxuridine - pharmacology | Cell Survival - drug effects | Tumor Stem Cell Assay | Proto-Oncogene Proteins - drug effects | Enzyme-Linked Immunosorbent Assay | Antibodies, Monoclonal - pharmacology | Docetaxel | Breast Neoplasms - drug therapy | DNA, Neoplasm - drug effects | Guanine Nucleotide Exchange Factors | Drug Synergism | Animals | Mice, Nude | Cyclophosphamide - pharmacology | Cell Line, Tumor | Mice | Vinblastine - pharmacology | Carboplatin - pharmacology | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Trastuzumab | Vinorelbine | Epirubicin - pharmacology | Chemotherapy | Care and treatment | Breast cancer | Research | Health aspects | Drug therapy | Medical treatment | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
by Pegram, Mark and Hsu, Sheree and Lewis, Gail and Pietras, Richard and Beryt, Malgorzata and Sliwkowski, Mark and Coombs, Daniel and Baly, Deborah and Kabbinavar, Fairooz and Slamon, Dennis
Oncogene, ISSN 0950-9232, 04/1999, Volume 18, Issue 13, pp. 2241 - 2251
Previous studies have demonstrated a synergistic interaction between rhuMAb HER2 and the cytotoxic drug cisplatin in human breast and ovarian cancer cells. To... 
Chemotherapy | Breast cancer | Synergy | Multiple drug effects analysis | HER-2/neu (c-erbB-2) | HER2/NEU-OVEREXPRESSING METASTATIC BREAST | synergy | GROWTH-FACTOR-RECEPTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTINEOPLASTIC AGENTS | breast cancer | MONOCLONAL-ANTIBODY | OVARIAN-CANCER | SALIVARY-GLAND | chemotherapy | ENDOMETRIAL CANCER | CELL BIOLOGY | C-ERBB-2 PROTEIN | ONCOLOGY | multiple drug effects analysis | TUMOR NECROSIS FACTOR | GENETICS & HEREDITY | GENE-PRODUCT | Recombinant Proteins - therapeutic use | Doxorubicin - therapeutic use | Adenocarcinoma - pathology | Receptor, ErbB-2 - genetics | Humans | Neoplasm Proteins - immunology | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Vinblastine - therapeutic use | Topoisomerase II Inhibitors | Antimetabolites, Antineoplastic - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Phosphorylation - drug effects | Neoplasm Proteins - genetics | Receptor, ErbB-2 - biosynthesis | Antibodies, Monoclonal - pharmacology | Etoposide - pharmacology | Combined Modality Therapy | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Drug Synergism | Antimetabolites, Antineoplastic - therapeutic use | Adenocarcinoma - therapy | Antibiotics, Antineoplastic - therapeutic use | Mice, Nude | Cyclophosphamide - pharmacology | Immunization, Passive | Fluorouracil - pharmacology | Mice | Cell Cycle - drug effects | Trastuzumab | Neoplasm Transplantation | Paclitaxel - pharmacology | Antibiotics, Antineoplastic - pharmacology | Antineoplastic Agents, Alkylating - pharmacology | Transplantation, Heterologous | Fluorouracil - antagonists & inhibitors | Cyclophosphamide - therapeutic use | Breast Neoplasms - therapy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Protein Processing, Post-Translational - drug effects | Female | Antineoplastic Agents - pharmacology | Thiotepa - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Neoplasm Proteins - biosynthesis | Etoposide - therapeutic use | Treatment Outcome | Cisplatin - pharmacology | Recombinant Proteins - pharmacology | Paclitaxel - therapeutic use | Neoplasms, Hormone-Dependent - therapy | Animals | Breast Neoplasms - pathology | Neoplasms, Hormone-Dependent - pathology | Vinblastine - pharmacology | Neoplasms, Hormone-Dependent - drug therapy | Doxorubicin - pharmacology | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Water-soluble and cleavable quercetin-amino acid conjugates as safe modulators for P-glycoprotein-based multidrug resistance
by Kim, Mi Kyoung and Choo, Hyunah and Chong, Youhoon
Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2014, Volume 57, Issue 17, pp. 7216 - 7233
Quercetinamino acid conjugates with alanine or glutamic acid moiety attached at 7-O and/or 3-O position of quercetin were prepared, and their multidrug... 
IN-VITRO | HYDROXYL-GROUPS | CHEMISTRY, MEDICINAL | CYCLOSPORINE-A | APIGENIN HOMODIMERS | BIVALENT MODULATORS | FLOW-CYTOMETRY | CANCER CELL-LINE | FLAVONOID DIMERS | PROTEIN-KINASES | REVERSAL | Paclitaxel - pharmacology | Antioxidants - chemistry | Models, Chemical | Antineoplastic Agents - chemical synthesis | Drug Resistance, Multiple - drug effects | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Amino Acids - chemistry | Alanine - chemistry | Amino Acids - pharmacology | Dose-Response Relationship, Drug | Antineoplastic Agents - pharmacology | Molecular Structure | Alanine - pharmacology | Cell Survival - drug effects | Quercetin - chemistry | Glutamic Acid - pharmacology | Antioxidants - pharmacology | Antineoplastic Agents - chemistry | Verapamil - pharmacology | Blotting, Western | Microscopy, Confocal | Quercetin - pharmacology | Cell Line, Tumor | Vinblastine - pharmacology | Dactinomycin - pharmacology | Doxorubicin - pharmacology | Glutamic Acid - chemistry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Myosin IIA regulates cell motility and actomyosin-microtubule crosstalk
by Conti, Mary Anne and Doyle, Andrew D and Even-Ram, Sharona and Matsumoto, Kazue and Adelstein, Robert S and Yamada, Kenneth M
Nature Cell Biology, ISSN 1465-7392, 03/2007, Volume 9, Issue 3, pp. 299 - 309
Non-muscle myosin II has diverse functions in cell contractility, cytokinesis and locomotion, but the specific contributions of its different isoforms have yet... 
ORGANIZATION | ADHESION | TRANSLOCATION | MIGRATING CELLS | CONTRACTILITY | CYTOSKELETON | RAC | DYNAMICS | MITOTIC KINESIN EG5 | INHIBITORS | CELL BIOLOGY | Nonmuscle Myosin Type IIA - antagonists & inhibitors | Embryonic Stem Cells - metabolism | RNA, Small Interfering - genetics | Embryonic Stem Cells - cytology | Humans | Nocodazole - pharmacology | Cercopithecus aethiops | Cell Movement - physiology | Heterocyclic Compounds, 4 or More Rings - pharmacology | Microtubules - metabolism | Nonmuscle Myosin Type IIB - antagonists & inhibitors | Transfection | Nonmuscle Myosin Type IIA - physiology | Guanine Nucleotide Exchange Factors - metabolism | Microtubules - drug effects | Nonmuscle Myosin Type IIA - genetics | Kinesin - genetics | Aminoquinolines - pharmacology | Kinesin - antagonists & inhibitors | T-Lymphoma Invasion and Metastasis-inducing Protein 1 | Nonmuscle Myosin Type IIB - physiology | Fibroblasts - metabolism | Guanine Nucleotide Exchange Factors - genetics | Nonmuscle Myosin Type IIB - genetics | Enzyme Inhibitors - pharmacology | Pyrimidines - pharmacology | Actomyosin - metabolism | Kinesin - metabolism | Naphthalenes - pharmacology | Azepines - pharmacology | Cell Movement - drug effects | Animals | Embryonic Stem Cells - drug effects | Cell Adhesion - physiology | Fibroblasts - drug effects | rac1 GTP-Binding Protein - antagonists & inhibitors | Fibroblasts - cytology | Mice | Vinblastine - pharmacology | Thiones - pharmacology | COS Cells | rac1 GTP-Binding Protein - metabolism | rac1 GTP-Binding Protein - genetics | Evaluation | Motility | Microtubules | Myosin | Physiological aspects | Genetic aspects | Properties | Health aspects | Cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text In vivo Therapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor
by Michiel S. van der Heijden and Jonathan R. Brody and David A. Dezentje and Eike Gallmeier and Steven C. Cunningham and Michael J. Swartz and Angelo M. DeMarzo and G. Johan A. Offerhaus and William H. Isacoff and Ralph H. Hruban and Scott E. Kern
Clinical Cancer Research, ISSN 1078-0432, 10/2005, Volume 11, Issue 20, pp. 7508 - 7515
Purpose: BRCA2, FANCC , and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to... 
BRCA1, BRCA2 | Xenograft models | DNA damage and repair mechanisms | Pharmacogenetics/pharmacogenomics | Gastrointestinal cancers: other | GENE-MUTATIONS | LUNG-CANCER | FUNCTIONAL-ACTIVITY | ONCOLOGY | ABL TYROSINE KINASE | MITOMYCIN-C | PANCREATIC-CANCER | RANDOMIZED-TRIAL | PHASE-II | COMPLEMENTATION GROUP | CARCINOMA | Paclitaxel - pharmacology | Apoptosis - drug effects | Cross-Linking Reagents - pharmacology | Humans | Deoxycytidine - pharmacology | Chlorambucil - pharmacology | Fanconi Anemia Complementation Group C Protein - genetics | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Caspases - metabolism | Fanconi Anemia Complementation Group G Protein - genetics | Time Factors | Cross-Linking Reagents - therapeutic use | Fanconi Anemia Complementation Group G Protein - deficiency | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Melphalan - pharmacology | Cell Survival - drug effects | Fanconi Anemia Complementation Group Proteins - deficiency | Mitomycin - therapeutic use | Pancreatic Neoplasms - pathology | Fanconi Anemia Complementation Group Proteins - genetics | Etoposide - pharmacology | Pancreatic Neoplasms - genetics | Cisplatin - pharmacology | Xenograft Model Antitumor Assays - methods | Mitomycin - pharmacology | Animals | Mice, Nude | Cell Line, Tumor | Fanconi Anemia Complementation Group C Protein - deficiency | BRCA2 Protein - deficiency | Fluorouracil - pharmacology | Mice | Vinblastine - pharmacology | Mutation | Cell Cycle - drug effects | BRCA2 Protein - genetics | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Communication between Multiple Drug Binding Sites on P-glycoprotein
by Catherine Martin and Georgina Berridge and Christopher F. Higgins and Prakash Mistry and Peter Charlton and Richard Callaghan
Molecular Pharmacology, ISSN 0026-895X, 09/2000, Volume 58, Issue 3, pp. 624 - 632
P-glycoprotein, a member of the ATP-binding cassette transporter family, is able to confer resistance on tumors against a large number of functionally and... 
CELLS | TRANSPORTER | MEDIATED MULTIDRUG-RESISTANCE | CHANNEL | PROGESTERONE | PRAZOSIN | MODULATORS | BIOCHEMISTRY & MOLECULAR BIOLOGY | LABELING SITES | PHARMACOLOGY & PHARMACY | TERTIARY STRUCTURE CHANGES | REVERSAL | Binding, Competitive | Cricetinae | Paclitaxel - pharmacology | ATP Binding Cassette Transporter, Subfamily B, Member 1 - drug effects | Allosteric Regulation | Tritium | Quinolines - pharmacology | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Rhodamine 123 - pharmacology | Animals | Benzylidene Compounds - pharmacology | Drug Interactions | Isoquinolines - pharmacology | Acridines - pharmacology | Benzimidazoles - pharmacology | Cell Membrane - metabolism | Vinblastine - pharmacology | Kinetics | Nicardipine - pharmacology | Radioligand Assay | Radiopharmaceuticals - pharmacology | Tetrahydroisoquinolines | Cell Membrane - drug effects | CHO Cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells
by Müller, Christine and Gross, Dietmar and Sarli, Vasiliki and Gartner, Michael and Giannis, Athanassios and Bernhardt, Günther and Buschauer, Armin
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2/2007, Volume 59, Issue 2, pp. 157 - 164
The inhibition of kinesin Eg5 by small molecules such as monastrol is currently evaluated as an approach to develop a novel class of antiproliferative drugs... 
Biomedicine | Chemosensitivity | Oncology | Cancer Research | Confocal microscopy | Human glioblastoma cells | Pharmacology/Toxicology | Kinesin inhibitors | Monastrol analogues | monastrol analogues | PROTEIN | P-GLYCOPROTEIN | PACLITAXEL | kinesin inhibitors | POTENT | ONCOLOGY | confocal microscopy | IN-VIVO | BIOLOGICAL EVALUATION | human glioblastoma cells | PHARMACOLOGY & PHARMACY | chemosensitivity | MULTIDRUG-RESISTANCE | BRAIN | Fluoresceins - pharmacology | Cysteine - analogs & derivatives | Flow Cytometry - methods | Paclitaxel - pharmacology | Tubulin Modulators - pharmacology | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Pyrimidines - chemistry | Dose-Response Relationship, Drug | Tubulin - metabolism | Spindle Apparatus - metabolism | Time Factors | Cysteine - pharmacology | Rotenone - pharmacology | Glioblastoma - metabolism | Molecular Structure | Kinesin - antagonists & inhibitors | Quinazolines - chemistry | Insecticides - pharmacology | Cell Survival - drug effects | Tetrahydroisoquinolines - pharmacology | Thiones - chemistry | Pyrimidines - pharmacology | Kinesin - metabolism | Acridines - pharmacology | Glioblastoma - pathology | Cell Line, Tumor | Cell Proliferation - drug effects | Spindle Apparatus - drug effects | Vinblastine - pharmacology | Thiones - pharmacology | Antineoplastic Agents, Phytogenic - pharmacology | Quinazolines - pharmacology | Brain tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs
by Frömberg, Anja and Gutsch, Daniela and Schulze, Daniel and Vollbracht, Claudia and Weiss, Gabriele and Czubayko, Frank and Aigner, Achim
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2011, Volume 67, Issue 5, pp. 1157 - 1166
While the benefits of ascorbic acid (vitamin C, ascorbate) as an essential nutrient are well established, its effects on tumor cells and in tumor treatment are... 
Prostate carcinoma | Medicine & Public Health | Paclitaxel | Cancer Research | Oncology | Ascorbate | Pharmacology/Toxicology | Dehydroascorbate | 5-FU | CANCER-CELLS | APOPTOSIS | DOSE VITAMIN-C | DEHYDROASCORBIC ACID | BREAST-CARCINOMA CELLS | IN-VITRO | MELANOMA | ONCOLOGY | GROWTH | PHARMACOLOGY & PHARMACY | HYDROGEN-PEROXIDE | MODULATION | Cell Survival - drug effects | Taxoids - pharmacology | Apoptosis - drug effects | Humans | Male | Organoplatinum Compounds - pharmacology | Drug Synergism | Prostatic Neoplasms | Vinblastine - analogs & derivatives | Ascorbic Acid - pharmacology | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Dehydroascorbic Acid - pharmacology | Vinblastine - pharmacology | Cell Cycle - drug effects | Camptothecin - pharmacology | Camptothecin - analogs & derivatives | Epirubicin - pharmacology | Drugs | Antimitotic agents | Care and treatment | Anthracyclines | Cell cycle | Drug therapy | Antineoplastic agents | Organic acids | Cancer | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1
by Robey, Robert W and Shukla, Suneet and Finley, Elizabeth M and Oldham, Robert K and Barnett, Daryl and Ambudkar, Suresh V and Fojo, Tito and Bates, Susan E
Biochemical Pharmacology, ISSN 0006-2952, 03/2008, Volume 75, Issue 6, pp. 1302 - 1312
Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2,... 
P-glycoprotein | MRP1 | Inhibitor | Drug resistance | CBT-1 | ABCG2 | ACUTE-MYELOID-LEUKEMIA | HUMAN LUNG-CANCER | MRP | BIRICODAR | CELL-LINES | COMBINATION | BREAST-CANCER | CYCLOSPORINE-A | inhibitor | CBT-1 (R) | P-glycoprotem | PHARMACOLOGY & PHARMACY | drug resistance | PHASE-I | EXPRESSION | Paclitaxel - pharmacology | Humans | Insecta | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Fluorescent Dyes - metabolism | Prazosin - metabolism | Prazosin - analogs & derivatives | Depsipeptides - pharmacology | Biological Factors - blood | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Cyclosporins - pharmacology | Quinolines - pharmacology | Alkaloids | Neoplasms - blood | Antineoplastic Agents - pharmacology | Biological Transport - drug effects | Azides - metabolism | Cell Line | Adenosine Triphosphatases - metabolism | Multidrug Resistance-Associated Proteins - antagonists & inhibitors | Verapamil - pharmacology | Neoplasms - drug therapy | Rhodamine 123 - metabolism | Animals | Biological Factors - pharmacokinetics | Cell Line, Tumor | ATP Binding Cassette Transporter, Sub-Family B | Fluorouracil - pharmacology | Vinblastine - pharmacology | Multidrug Resistance-Associated Proteins - metabolism | Biological Factors - pharmacology | Index Medicus | drug-resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Co-treatment with the anti-malarial drugs mefloquine and primaquine highly sensitizes drug-resistant cancer cells by increasing P-gp inhibition
by Kim, Yong Kee and Kim, Ju-Hwa and Choi, Ae-Ran and Yoon, Sungpil
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 11/2013, Volume 441, Issue 3, pp. 655 - 660
The purpose of this study was to identify conditions that will increase the sensitivity of resistant cancer cells to anti-mitotic drugs. Currently, atovaquine... 
Anti-malarial drugs | Mefloquine | Vinblastine | P-gp | Drug-resistance | Primaquine | APOPTOSIS | UTERINE CARCINOSARCOMA | MICROTUBULES | BIOCHEMISTRY & MOLECULAR BIOLOGY | DNA-DAMAGE | DOXORUBICIN | AUTOPHAGY | CHEMOTHERAPY | BREAST-CANCER | IN-VITRO | BIOPHYSICS | AGENTS | Mefloquine - pharmacology | Apoptosis - drug effects | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Verapamil - pharmacology | Antimalarials - pharmacology | Chloroquine - pharmacology | Artemisinins - pharmacology | Cell Line, Tumor | Doxycycline - pharmacology | Primaquine - pharmacology | Antineoplastic Agents - pharmacology | Vinblastine - pharmacology | Drug Resistance, Neoplasm - drug effects | Drugs | Malaria | Cancer cells | Drug resistance | Drug therapy | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells
by van Leeuwen, Ingeborg M.M and Rao, Bhavya and Sachweh, Marijke C.C and Lain, Sonia
Cell Cycle, ISSN 1538-4101, 05/2012, Volume 11, Issue 9, pp. 1851 - 1861
Pharmacological activation of wild-type p53 has been found to protect normal cells in culture from cytotoxicity and nuclear aberrations caused by conventional... 
Nutlin-3 | actinomycin D | tenovin-6 | leptomycin B | cyclotherapy | chemoprotection | p53 | Proteins | Binding | Landes | Calcium | Biology | Bioscience | Cell | Cycle | Organogenesis | Cancer | Actinomycin D | Tenovin-6 | Chemoprotection | Cyclotherapy | Leptomycin B | CANCER-CELLS | MICROTUBULE-ACTIVE DRUGS | nutlin-3 | LEPTOMYCIN-B | NUCLEAR EXPORT | TETRAPLOID CELLS | ACTINOMYCIN | RIBOSOMAL-PROTEIN L11 | CELL BIOLOGY | INHIBITION | IN-VIVO | MDM2 | Cytarabine - pharmacology | Cell Survival | Cell Count | HCT116 Cells | Humans | Tumor Suppressor Protein p53 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Fatty Acids, Unsaturated - pharmacology | Imidazoles - pharmacology | Piperazines - pharmacology | Tumor Suppressor Protein p53 - genetics | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Vinblastine - analogs & derivatives | Antineoplastic Agents - adverse effects | Cell Cycle Checkpoints - drug effects | Vinca Alkaloids - pharmacology | Fibroblasts - drug effects | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Cell Proliferation - drug effects | Vinblastine - pharmacology | Dactinomycin - pharmacology | Drug Screening Assays, Antitumor | Index Medicus | Report
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent
by Jost, Marco and Chen, Yuwen and Gilbert, Luke A and Horlbeck, Max A and Krenning, Lenno and Menchon, Grégory and Rai, Ankit and Cho, Min Y and Stern, Jacob J and Prota, Andrea E and Kampmann, Martin and Akhmanova, Anna and Steinmetz, Michel O and Tanenbaum, Marvin E and Weissman, Jonathan S
Molecular Cell, ISSN 1097-2765, 10/2017, Volume 68, Issue 1, pp. 210 - 223.e6
Chemical libraries paired with phenotypic screens can now readily identify compounds with therapeutic potential. A central limitation to exploiting these... 
CRISPRi | chemical genetics | genome-wide CRISPR screening | rigosertib | microtubules | CRISPRa | drug target identification | drug mechanism of action | PROTEIN | COLCHICINE | SMALL MOLECULES | MECHANISM | BIOCHEMISTRY & MOLECULAR BIOLOGY | GENOMIC ASSAYS | TARGETS | RISK MYELODYSPLASTIC SYNDROMES | TUBULIN | INHIBITOR | BINDING AGENTS | CELL BIOLOGY | Colchicine - pharmacology | Glycine - analogs & derivatives | Small Molecule Libraries - pharmacology | RNA, Guide - genetics | RNA, Guide - metabolism | Tubulin Modulators - pharmacology | Humans | Gene Expression Regulation, Neoplastic | Drug Resistance, Neoplasm | Tubulin - genetics | Sulfones - pharmacology | Genetic Testing - methods | Recombinant Fusion Proteins - metabolism | Lentivirus - metabolism | Microtubules - metabolism | Tubulin - metabolism | Glycine - chemistry | Microtubules - drug effects | Sulfones - chemistry | Microtubules - ultrastructure | Kinesin - genetics | Lentivirus - genetics | Antineoplastic Agents - pharmacology | Tubulin - chemistry | Myelodysplastic Syndromes - metabolism | Tubulin Modulators - chemistry | Genetic Vectors - chemistry | Genetic Vectors - metabolism | Antineoplastic Agents - chemistry | Kinesin - metabolism | Glycine - pharmacology | CRISPR-Cas Systems | K562 Cells | Recombinant Fusion Proteins - genetics | Myelodysplastic Syndromes - genetics | Vinblastine - pharmacology | HeLa Cells | Mutation | Myelodysplastic Syndromes - pathology | Tubulins | Genomics | Genetic screening | Biochemical genetics | Cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights